Tepezza and Atrial fibrillation/flutter - a phase IV clinical study of FDA data

Summary:

Atrial fibrillation/flutter is reported as a side effect among people who take Tepezza (teprotumumab-trbw), especially for people who are have been taking the drug for < 1 month also take Vitamin D3, and have Endocrine ophthalmopathy.

The phase IV clinical study analyzes which people have Atrial fibrillation/flutter when taking Tepezza. It is created by eHealthMe based on reports of 3,630 people who have side effects when taking Tepezza from the FDA, and is updated regularly.

What is Tepezza?

Tepezza has active ingredients of teprotumumab-trbw. eHealthMe is studying from 3,632 Tepezza users. Check the latest studies of Tepezza.

What is Atrial fibrillation/flutter?

Atrial fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles) is found to be associated with 2,362 drugs and 3,844 conditions by eHealthMe. Check the latest studies of Atrial fibrillation/flutter.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

3,630 people reported to have side effects when taking Tepezza.
Among them, 14 people (0.39%) have Atrial fibrillation/flutter.

Could Tepezza cause Atrial fibrillation/flutter?

Among these 14 people:

How long have people been on Tepezza when they have Atrial fibrillation/flutter? *

What are other drugs people take besides Tepezza? *

What are other side effects people have besides Atrial fibrillation/flutter? *

Full Blood Count Decreased: 2 people, 14.29%
Fainting (loss of consciousness and postural tone): 2 people, 14.29%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 14.29%
Ear Discomfort: 2 people, 14.29%
Heart Rate Increased: 2 people, 14.29%
Dyspnea Exertional: 2 people, 14.29%
High Blood Pressure: 2 people, 14.29%
Dizziness: 2 people, 14.29%
Hypotension (abnormally low blood pressure): 2 people, 14.29%
Muscle Spasms (muscle contraction): 2 people, 14.29%

What are the existing conditions these people have? *

Endocrine Ophthalmopathy (increased water content of retroocular orbital tissues; associated with thyroid disease, usually hyperthyroidism): 9 people, 64.29%
Basedow's Disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones): 3 people, 21.43%
Type 2 Diabetes: 2 people, 14.29%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 14.29%
Neuropathy Peripheral (surface nerve damage): 2 people, 14.29%
Hypersensitivity: 2 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 14.29%
Vision Blurred: 1 person, 7.14%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 7.14%
Hyperglycemia (high blood sugar): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Tepezza and have Atrial fibrillation/flutter?

- Check whether Atrial fibrillation/flutter is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tepezza:

Tepezza (3,632 reports)

Browse all side effects of Tepezza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Atrial fibrillation/flutter:

Atrial fibrillation/flutter (2,362 drugs)

Browse all the conditions that are associated with Atrial fibrillation/flutter:

Atrial fibrillation/flutter (3,844 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on teprotumumab-trbw (the active ingredients of Tepezza) and Tepezza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.